Made this list. If you are not a subscriber you can copy and paste the link into a google search (not the address bar), then click on the article again and you will then be able to read the full article.
"Tim Blue's top 100 picks for 2013"
"33. ACRUX (ACR)
A biotech in sharemarket disfavour yet on the verge of US take-up of its Axiron testosterone replacement product in a $1.3bn-a-year industry. BBY thinks if Axiron captures 20 per cent of that market it could be worth $4.24 a share. Partner Eli Lilly will be launching a direct-to-consumer advertising campaign in the near term, while US health insurers are picking up reimbursement coverage of the product. A strong buy, says BBY."
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)